CLINICAL TRIALS PROFILE FOR LINEZOLID

505(b)(2) Clinical Trials for LINEZOLID

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT01734694 ↗	Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients	Terminated	Henry Ford Health System	Phase 4	2011-10-01	For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due to various reasons, including new dosing recommendations as well as an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity. This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin use.
New Dosage	NCT02778828 ↗	Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis	Completed	Groupe Hospitalier Paris Saint Joseph	N/A	2015-11-04	Linezolid, primary treatment for MDR-TB combination therapy anti. Until it is the dose of 600 mg x1 / day, rather sensible for most patients is more, which was unanimous. It is true that if a dosage is consensus, it goes without saying, because of the interindividual variability, marked moreover to linezolid, a therapeutic monitoring assay of plasma levels is indispensable for most pharmacological treatments. This therapeutic drug monitoring (TDM) often gives rise, as known, to dosage changes. It turns out that at present no real STP on the basic objectives PK / PD is really made in France in the treatment of tuberculosis (TB) and the bibliography remains rather poor recommendations, and yet all the elements are there: indeed linezolid is an antibiotic whose activity is purely "time-dependent". So one should fulfill 2 PK / PD objectives whose precise boundaries are sometimes still to be determined: -% T> MIC, or percentage of time spent with plasma concentrations above the minimum inhibitory concentration of linezolid (LNZ) for Mycobacterium tuberculosis. In practice, the residual concentration before the next shot must be> MIC (0.125 to 1 mg / l) - A fortiori it must also take into account the concentration preventing the appearance of resistant mutants, amounting to 1.2 mg / l - AUC / MIC> 80, or ratio of the area under the curve (AUC, Area under curve) of plasma concentration versus time and CMI LNZ Until then, and without real bibliographic support, and for the sake of kindness to patients coupled with an economic advantage, the STP consisted of 2 samples, a peak 1:30 after taking (Cmax) and a residual before taking (C min) , after all, to 600mg x1 / 24 correlates well with the AUC (55% peak and 75% for the residual). Following an observation that 25 to 30% of patients had a C min
New Indication	NCT05069974 ↗	Alternative Antibiotics for Syphilis	Recruiting	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	Phase 3	2021-10-01	The Trep-AB clinical trial will test the efficacy of an investigational neuropenetrative drug, Linezolid (LZD), compared to standard treatment, Benzathine penicillin G (BPG), for early syphilis in humans. The overarching idea of the work proposed herein is to investigate the use of LZD to treat syphilis, conducting a randomized controlled clinical trial to evaluate this new indication of a known antibacterial agent. It is estimated to include 360 participants.

All Clinical Trials for LINEZOLID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00035269 ↗	New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)	Completed	Pfizer	Phase 3	2001-12-01	This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
NCT00035425 ↗	Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection	Completed	Pfizer	Phase 3	2001-11-01	This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).
NCT00035854 ↗	New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)	Completed	Pfizer	Phase 3	2002-02-01	This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
NCT00037050 ↗	Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria	Completed	Pfizer	Phase 3	2002-04-01	This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)
NCT00042289 ↗	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)		2003-03-01	The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00042289 ↗	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)		2003-03-01	The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00084266 ↗	Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)	Completed	Pfizer	Phase 4	2004-10-01	To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects. Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia which will be treated with either linezolid or vancomycin.

Clinical Trial Conditions for LINEZOLID

Condition Name

Condition Name for LINEZOLID
Intervention	Trials
Tuberculosis	15
Pulmonary Tuberculosis	12
Bacterial Infections	9
Tuberculosis, Multidrug-Resistant	9

Condition MeSH

Condition MeSH for LINEZOLID
Intervention	Trials
Infections	46
Tuberculosis	46
Infection	44
Communicable Diseases	40

Clinical Trial Locations for LINEZOLID

Trials by Country

Trials by Country for LINEZOLID
Location	Trials
United States	438
China	126
South Africa	70
Japan	42
Brazil	29

Trials by US State

Trials by US State for LINEZOLID
Location	Trials
California	32
Texas	26
Ohio	24
Georgia	23
Florida	22

Clinical Trial Progress for LINEZOLID

Clinical Trial Phase

Clinical Trial Phase for LINEZOLID
Clinical Trial Phase	Trials
PHASE4	5
PHASE3	5
PHASE2	2

Clinical Trial Status

Clinical Trial Status for LINEZOLID
Clinical Trial Phase	Trials
Completed	75
Recruiting	31
Not yet recruiting	15

Clinical Trial Sponsors for LINEZOLID

Sponsor Name

Sponsor Name for LINEZOLID
Sponsor	Trials
Pfizer	30
Beijing Chest Hospital	9
National Institute of Allergy and Infectious Diseases (NIAID)	8

Sponsor Type

Sponsor Type for LINEZOLID
Sponsor	Trials
Other	318
Industry	91
NIH	10

Last updated: July 26, 2026

nezolid Clinical Trials Update, Market Analysis, and Market Projection (2026–2035)
Linezolid remains a mature, off-patent antibacterial used for serious Gram-positive infections, including MRSA and VRE. Demand is sustained by hospital formularies and stewardship-driven use, with incremental growth supported by newer fixed-dose regimens in select geographies, but limited by broad generic availability and price compression. Near-term R&D activity is concentrated on expanded indications, safety/tolerability in special populations, optimized dosing strategies, and novel delivery systems, rather than platform-changing new chemistry.

---

What is the latest clinical trials update for linezolid (2025–2026)?

Answer: Current clinical activity is skewed to pharmacokinetics/pharmacodynamics (PK/PD), real-world outcomes, and subgroup safety rather than late-stage Phase 3 registration in the US-EU core label categories.

Key trial themes showing up in recent linezolid investigations

• Dosing optimization
  Trials evaluate dosing strategies for renal impairment, obesity, pediatrics, burn patients, and prolonged therapy courses, with endpoints focused on trough concentrations, mitochondrial safety markers, and clinical cure rates.
• Safety and tolerability in prolonged use
  Studies track risk signals tied to long courses, including thrombocytopenia and peripheral/optic neuropathy. Designs often use prospective observational elements or pragmatic cohorts.
• Combination regimens and resistance dynamics
  Linezolid is assessed in combination strategies against difficult Gram-positive infections with attention to microbiologic eradication and relapse.
• Novel formulations and routes
  Work continues on alternative presentations to improve administration convenience and adherence in inpatient settings, including ready-to-use or extended stability products.

How to interpret “update” for a mature drug

Linezolid has limited “new molecule” trial velocity because core uses are already established and generics dominate. Most activity targets incremental value:

• regulatory post-approval label refinements (dose, populations, safety monitoring)
• product lifecycle improvements (formulation, stability, administration practicality)
• evidence generation for stewardship and guideline alignment

---

Which linezolid indications are still driving clinical development?

Answer: The highest study density is for serious Gram-positive infections where clinicians need predictable activity against MRSA, including complicated skin and skin structure infections and hospital-acquired infections, plus difficult-to-treat settings such as ventilator-associated or catheter-related infections.

Indication clusters

• MRSA-associated infections Trials often measure time-to-clinical response, microbiologic clearance, and relapse at follow-up.
• VRE-associated infections Evidence generation focuses on outcomes where therapeutic options are limited.
• Pneumonia and bacteremia subtypes Endpoints emphasize clinical cure, microbiologic response, and safety in longer courses.
• Special populations Pediatrics, renal impairment, and critically ill populations where PK variability can drive adverse event risk.

---

What is the current FDA and regulatory status of linezolid products (Orange Book view)?

Answer: Linezolid is represented by multiple approved branded and generic drug products across dosage forms (tablets, suspension, and IV), with listing on the FDA Orange Book for approved active ingredients and their related patents.

Practical regulatory reality

• Brand-origin patents are largely expired.
• Patent estates remain mainly in the form of:
  • formulation and manufacturing-related patents for specific NDA/BLA product families
  • method-of-use and new-use exclusivities in limited contexts
• Generic entry has already occurred widely, which constrains market pricing power to product-specific and supply-chain-specific factors.

---

What is the market size and growth outlook for linezolid (2026–2035)?

Answer: Linezolid is a mature hospital antibiotic market. Growth is likely to be modest and value-led rather than volume-led, with sustained baseline demand and competition-driven price compression.

Market drivers that support baseline demand

• Hospital utilization for MRSA/VRE
  Stewardship continues to reserve linezolid for resistant Gram-positive infections and cases where alternatives fail or are contraindicated.
• Repeat admissions and infection recurrence
  Patient-level persistence of risk across comorbidities keeps usage consistent even as annual incidence fluctuates.
• Limited alternatives in certain settings
  Resistance patterns can increase linezolid’s share versus other agents depending on regional antibiogram changes.

Market headwinds that limit sustained growth

• Generic penetration and price erosion
• Safety-monitoring burden Longer courses require platelet and neuropathy monitoring, which can reduce elective use.
• Guideline-driven sequencing Where newer MRSA agents or beta-lactams with MRSA activity are preferred, linezolid share can shift.

Projection framework (directional, business-useful)

• Volume: flat-to-slightly positive, tied to infection burden and hospital case mix.
• Price: declining in competitive geographies; stabilizing where tender dynamics or supply constraints occur.
• Value: low-to-mid single-digit growth is more plausible than high growth given generic pressure.

---

How do generic linezolid dynamics affect market pricing and margins?

Answer: Generic entry is the primary determinant of price and margin compression, with brand-like pricing only feasible for specific channels, tender contracts, or supply constraints.

Where margins remain structurally supported

• IV products and supply chain continuity
• Hospital formularies with switching inertia
• Regional tender structures that favor continuity of supply
• Product differentiation through presentation Concentration, stability, package size, and administration convenience can influence procurement decisions even when APIs are interchangeable.

Where margins are structurally pressured

• Wholesale and contract-based bidding
• Multiple interchangeable suppliers driving down acquisition cost
• Inventory availability When supply is stable, buyers push toward lowest-cost bids.

---

Which companies are the leading manufacturers of linezolid generics, and how does that shape competition?

Answer: Competition is defined by multi-supplier generic portfolios across tablets and IV solutions, with tender-based share shifts and periodic supply disruptions influencing local pricing.

Competitive structure

• Multi-source generics Most demand is split among several manufacturers, reducing ability for any single player to sustain elevated pricing.
• Portfolio breadth Companies offering both oral and IV forms can reduce substitution friction for hospitals.

Commercial implications

• Market share is less driven by clinical differentiation and more by:
  • national tender wins
  • distribution reach
  • reliable IV supply
  • contracting terms

---

What patent estate risks exist for linezolid (generic entry barriers, formulations, and methods)?

Answer: For linezolid as an active ingredient, major exclusion risk is low in most mature markets, but product-level patents can still matter for specific brand-origin product families or formulations, especially where IV or stability-optimized presentations are protected.

What types of patents can still matter

• Formulation patents
  • excipients, concentration, stability, controlled release attributes (where applicable)
• Manufacturing and process patents
  • sterilization, lyophilization, impurity control
• Method-of-use patents
  • typically limited to narrow patient subsets or dosing/monitoring strategies

Why litigation risk is typically lower than for newer drugs

• Linezolid has had long market history, enabling broad generic entry.
• Remaining legal leverage is usually confined to narrow product families.

---

Has linezolid faced Paragraph IV challenges or patent litigation historically, and what is the current litigation posture?

Answer: Linezolid has had patent litigation historically during periods of generic entry, but the market is now largely settled with multiple approved versions. Current litigation posture is less likely to create major market-wide exclusivity changes.

Typical settlement effects when they occurred

• delayed generic launch windows via settlement agreements
• narrow launch designs tied to non-infringing formulations/processes

Current business relevance

• Focus shifts from “blockade” to:
  • product continuity
  • supply reliability
  • procurement timing

---

When does linezolid lose exclusivity, and how does exclusivity differ by market and product?

Answer: For linezolid’s core branded active ingredient, exclusivity related to original NDA approvals has largely passed. What remains is product-specific patent coverage for particular presentations and formulations, plus any ongoing pediatric or regulatory exclusivity windows tied to specific product line events.

Exclusivity vs patent expiry in practice

• Exclusivity: defines the ability to file or approve, often anchored to approval dates.
• Patents: define infringement exposure for specific formulations, processes, or uses.
• In a generic-saturated market, the practical “launch gating” is driven more by patent-by-product than drug-by-drug.

---

How strong is the patent estate for linezolid compared with other Gram-positive antibiotics?

Answer: Compared with newer MRSA agents with active, broad estates, linezolid’s enforceable IP is comparatively limited in scope and commercial impact. Remaining value is primarily in formulation/process patents tied to specific branded product lineages.

Competitive comparison logic (high-level)

• Newer agents may offer:
  • longer patent runways
  • differentiated administration features
  • payer-specific formulary pull-through
• Linezolid competes on:
  • proven efficacy
  • clinician familiarity
  • price and supply reliability

---

Which alternative antibiotics compete with linezolid, and how does that affect linezolid demand?

Answer: Competition comes from other MRSA-active and Gram-positive agents, plus agents preferred for safety or stewardship in certain settings.

Main competitive forces

• MRSA-targeted beta-lactams or newer anti-MRSA agents
• Glycopeptides where used for specific scenarios
• Other linezolid-like oral/IV options depending on regional resistance patterns

Share-shift drivers

• drug acquisition cost under tenders
• safety profiles and monitoring burden
• local antibiogram and formulary restriction rules

---

What market risks exist for linezolid (safety, procurement, and resistance)?

Answer: The key risks are clinical safety monitoring constraints, supply chain and tender volatility, and stewardship-driven restriction based on emerging comparative evidence or local resistance patterns.

Safety-related commercial risks

• thrombocytopenia with prolonged therapy
• neuropathy signals that raise monitoring and discontinuation risk
• drug-drug interactions driven by monoamine oxidase inhibition properties (where relevant)

Procurement risks

• concentrated purchasing power at health system and national accounts
• tender cycles that force steep price resets

Resistance and microbiology risks

• if MRSA/VRE epidemiology shifts away from linezolid-sensitive strains, or if cross-resistance rises

---

What commercial upside exists for linezolid in select formulations or geographies?

Answer: Upside is most plausible where:

• IV supply reliability is scarce
• tender structures value continuity
• formulation patents protect specific presentations longer than the API-level market
• stewardship protocols favor linezolid as a reserved option with stable utilization

Where upside is most likely

• hospital-heavy geographies with large inpatient cohorts
• markets where branded-to-generic switching is slower due to supply constraints or contracting inertia
• countries with product-level patent entitlements that are still active

---

Key Takeaways

• Linezolid clinical activity in 2025–2026 is concentrated on dosing optimization, special populations, safety monitoring, and formulation/process value rather than new blockbuster indication expansion.
• Market growth is likely modest and primarily value-led, with generic-driven price compression limiting upside.
• Competitive dynamics are dominated by multi-source generics, making procurement, supply reliability, and product presentation more important than differentiation.
• Patent leverage is mostly product-specific after broad generic entry, so commercial gating is product-family and jurisdiction-specific rather than drug-wide.

---

FAQs

1) What are the most common adverse events associated with linezolid in clinical practice?

Thrombocytopenia and gastrointestinal events are among the most monitored. Prolonged therapy increases attention to neuropathy and myelosuppression risk.

2) Does linezolid require therapeutic drug monitoring?

Many settings rely on PK-informed dosing and monitoring of safety parameters. TDM practices vary by hospital protocols, patient risk factors, and course duration.

3) Is linezolid used for MRSA pneumonia, and what endpoints do trials emphasize?

Use varies by guideline position and local formulary rules. Trials typically emphasize clinical cure, microbiologic eradication, safety, and relapse at follow-up.

4) What drives tender selection for linezolid IV versus oral tablets?

IV continuity, package convenience, stability shelf-life, and contracted pricing drive most selection decisions in hospital procurement.

5) Are there biosimilar concerns for linezolid?

No. Linezolid is a small-molecule antibiotic, so biosimilar frameworks do not apply.

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. ClinicalTrials.gov. Linezolid (search results). U.S. National Library of Medicine. https://clinicaltrials.gov/
3. IDSA guidelines and stewardship materials for MRSA and Gram-positive infections (latest published versions). Infectious Diseases Society of America. https://www.idsociety.org/